ArticleTherapeutic advances in pulmonary and critical care medicine
Effectiveness of Nirmatrelvir/Ritonavir in Unvaccinated COVID-19 Patients Treated in the Emergency Department: A Retrospective Propensity-Matched Cohort Analysis.
Article in Therapeutic advances in pulmonary and critical care medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: Nirmatrelvir/Ritonavir (nir/rit) is an antiviral combination, often sold under the brand name Paxlovid, used to treat COVID-19, particularly in high-risk individuals. Numerous COVID-19 treatments exist, but clinical studies have reported conflicting data on their efficacy, particularly in unvaccinated patients. Objectives: This study aims to compare 28-day mortality, hospitalization, intensive care unit (ICU) admission, observation status, and hypoxia rates among unvaccinated COVID-19 patients treated with nir/rit in the emergency department (ED) versus those who did not receive nir/rit. Design: This retrospective, propensity-matched cohort study utilized the TriNetX database, which included records of 112 million patients from 64 academic medical centers and healthcare organizations across the U.S. The study period was 2022-2024. Methods: The treatment cohort consisted of COVID-19-unvaccinated ED patients aged 18 and above who tested positive for COVID-19 via RNA test and were administered nir/rit on the same day. Patients admitted for observation or inpatient care on the same day were excluded. Outcomes assessed within 28 days post-ED diagnosis included mortality, ICU admission, inpatient hospitalization, observation status, and hypoxia (O Results: A total of 194 181 unvaccinated COVID-19 patients were identified, with 14 799 receiving nir/rit and 179 382 not receiving it. After propensity matching, 14 799 patients were included in each cohort. Paxlovid treatment was associated with lower mortality (risk ratios [RR] = 0.28, Conclusions: Nir/rit treatment in unvaccinated adults diagnosed with COVID-19 in the ED is associated with significantly lower mortality, ICU admissions, hospitalizations, observation status, and hypoxia, supporting its use in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.